Chapter 3: Differential bacterial surface display of peptides by the transmembrane domain of OmpA

Abstract

We have displayed the highly charged and hydrophilic 3xFLAG and 2xmyc epitopes on the surface of *Escherichia coli* by inserting them in surface exposed loops of the transmembrane (TM) domain of OmpA. These OmpA TM domain variants were examined for their stability and membrane incorporation in vivo. We show that these constructs are incorporated in the outer membrane (OM), and that intact cells can be fluorescently labelled with antibodies against the epitope insertions. However, all suffer from degradation and are present in the cell at approximately 10% of the TM domain concentration without epitope tag inserted. As wild-type OmpA contains an additional C-terminal periplasmic domain, we investigated if addition of this domain would have a beneficial effect on the protein levels of the 3xFLAG variants. Our data demonstrate that this is not the case. In contrast, insertion of a neutrally charged SA-1 peptide in the TM domain of OmpA does not affect protein levels at all. These results suggest an incompatibility of the widely used negatively charged 3xFLAG and 2xmyc epitopes with the biogenesis pathway of OmpA that could have implications for the random selection of peptides displayed on the Gram-negative cell surface.
Introduction

Integral outer membrane proteins (OMPs) are a class of proteins that are embedded in the bacterial outer membrane (OM) as β-barrels. Among these, Outer membrane protein A (OmpA) is a very abundant (typically about $10^5$ copies/cell (Koebnik et al. 2000)) and widely studied OMP, and considered a model system for outer membrane insertion (Koebnik 1999; Kleinschmidt 2006). OmpA has four surface exposed loops. In the field of molecular recognition, the OmpA protein has been used as a bacterial surface display system, where combinatorial peptide libraries are displayed on the cell surface via one of its surface exposed loops (Bessette et al. 2004). This allowed high-throughput screening for peptides that bind with high affinity to a desired target. In this way, the authors identified inserted peptides that bind streptavidin with high affinity. Their highest affinity peptide (SA-1) had an equilibrium dissociation constant in the low nanomolar range.

The full-length, processed OmpA protein (325 residues) consists of two domains, a N-terminal transmembrane (TM) domain of 170 residues, connected via a short 19-residue Ala-Pro rich hinge region to a C-terminal periplasmic domain of 136 residues (Chen et al. 1980). The periplasmic domain plays an important structural role in the periplasm, tethering the OM to the peptidoglycan layer (a function shared with Braun’s lipoprotein Lpp, and the lipoprotein Pal (for references consult (den Blaauwen et al. 2008)). For a comprehensive review on OmpA structure and function see (Smith et al. 2007).

In vivo, genetically truncated OmpA-171 consisting of only the TM domain assembles into the outer membrane as efficiently as the full-length protein. This has been shown using protease digestion combined with heat-modifiability experiments (Ried et al. 1994). In these experiments, the authors made use of the fact that when isolated cell membranes are treated with proteases (such as trypsin or proteinase K), the periplasmic domain of OmpA is digested, but its TM domain is protected by the outer membrane (Chen et al. 1980).

Our goal was to create an anchoring point on the bacterial cell surface that could act as a handle in biophysical force experiments. Therefore, we have inserted the epitope tags 3xFLAG and 2xmyc into loop 2 and 3 of the transmembrane domain of OmpA, and studied their stability and outer membrane incorporation in vivo. As the cell wall anchoring by the periplasmic domain was unwanted in these experiments, the TM domain of OmpA was...
initially used instead of the full-length protein.

We show that these engineered OmpA TM domain variants can be incorporated into the OM, but suffer from degradation, and are present at reduced levels (approximately 10% compared to the TM domain level without epitope insertion). This was unexpected, since it has been shown that similar-sized insertions in loop 2 or 4 did not reduce protein levels at all (Freudl 1989). Since to our knowledge, all \textit{in vivo} loop insertions to date have been made in full-length OmpA, we investigated a possible stabilizing role of the periplasmic domain. Our data demonstrate that the periplasmic domain did not stabilize the 3xFLAG insertion variants. These results suggest an incompatibility of 3xFLAG and 2xmyc tags with the biogenesis pathway of OmpA. The reason for the inefficient display of the 3xFLAG and 2xmyc peptides may be their strong (negative) charges. Using the neutrally charged peptide tag SA-1 we show that it is possible to insert a peptide in the TM domain of OmpA that is expressed at similar protein levels as the TM domain without insertion. Apparently OmpA does not display all small peptides equally efficient, which can have consequences for applications in which OmpA is used as a carrier of randomly generated peptide libraries. Certain peptides would be inefficiently displayed, leading to a bias during the selection process (Lee et al. 2003). Whether these results are specific for OmpA or reflect a more general constraint on surface-exposed loops remains to be established. These results could also be of interest for biotechnological applications based on antigen-displaying \textit{E. coli} cells, e.g. to capture and isolate antibody-displaying phage (Benhar 2001).
Chapter 3

Materials and Methods

Bacterial strains and growth conditions

_E. coli_ strains (Table 1) were grown at 37°C in TY medium containing 1% Bacto trypton, 0.5% Bacto yeast extract, 0.5% NaCl and 3 mM NaOH. Expression of the constructs was induced by adding up to 1 mM IPTG or 0.02% L-arabinose, depending on the plasmid vector. Antibiotics were ampicillin (100 μg/ml) or Chloramphenicol (25 μg/ml). LMC500 (MC4100 _lysA_) was made chemically competent using the calcium chloride method. MC1061 and its derivative MC1061 ΔOmpA were transformed using electroporation.

Constructs

All DNA manipulation, analysis and bacterial transformations were performed according to standard protocols (Sambrook et al., 1989). All PCR fragments were sequenced, either at Baseclear (Leiden) or at the AMC DNA sequencing facility (Amsterdam Medical Centre). Primers were ordered from MWG or Biolegio, and Advantage DNA polymerase (Clontech) or pfuTurbo DNA polymerase (Stratagene) was used for the PCR reactions. The cloning steps performed to obtain the plasmids are described in the Supplementary Materials and Methods.

Preparation of cell lysates

Fresh overnight cultures grown at 37°C were diluted 1000x into 50-100 ml fresh TY medium and cultured at 37°C. Growth was monitored by measurement of the optical density at 600 nm with a spectrophotometer (Perkin-Elmers). IPTG was added at around an OD600 of 0.1, and when the cells reached an OD600 of 1.0, they were transferred to a 50 ml Falcon tube and put on ice. The cells were then collected by centrifugation for 15 min at 4000 rpm in a tabletop centrifuge at 4°C (Eppendorf). The supernatant was carefully removed, and the cells were resuspended in ice-cold sonication buffer (10 mM Tris-HCl buffer, pH 7.9, supplemented with 1 mM EDTA and 1 tablet of Roche Protease Inhibitor Cocktail), at a concentration corresponding to an OD600 of 250. This cell suspension was transferred to a 2 ml Eppendorf tube, and sonicated on ice with a tip sonicator (Branson) in 4-5 10-second bursts with 10 second cooling in between each burst. Debris and intact cells were pelleted in a 4°C cooled centrifuge at 2700 x g for 2 min. The supernatant was
Differential surface display of peptides

transferred to a 1.5 ml Eppendorf tube and frozen at -20°C as total cell lysate.

Fractionation of cell lysates

After thawing, the cell lysate was diluted to 4 ml (corresponding to an OD600 of 12.5), and 100 μl of this was saved as “total cell lysate”. The samples were pelleted at 45000 rpm (corresponding to 200,000 x g) for 45 min in an ultracentrifuge (Beckman-Coulter). After centrifugation, 500 μl was saved as “supernatant”. The membrane pellet was resuspended in 100 μl sonication buffer and frozen at -20°C.

SDS-PAGE and Western blotting

For SDS-PAGE, samples were mixed with sample buffer (end concentration: 62.5 mM Tris pH 6.8, 2% SDS, 10% glycerol, 2% 2-mercaptoethanol) and either heated to 99°C for 5 min or heated to 50°C for 15 min and electrophoresed on 15% polyacrylamide slabs. Anti-FLAG and anti-myc monoclonal antibodies used for the immunoblots were obtained from Sigma and Roche, respectively. The polyclonal anti-OmpA antibody was a kind gift from A. Driessen (University of Groningen, Netherlands). The bands were detected using the ECL+ chemiluminescence kit (Amersham) and scanning with a STORM 860 fluorescence imager. Densitometry was performed using ImageJ (http://rsb.info.nih.gov/ij/). The mean pixel value of a rectangular region was calculated close but outside a band of interest to calculate the mean background pixel value. The same selection rectangle was positioned to include the band of interest, and again a mean pixel value is calculated. Subtraction then gives a band intensity value. All band comparisons were performed using the same selection rectangle.

Fluorescent labeling of fixed cells

Cells were fixed in 2.8% formaldehyde (FA) and 0.04% glutaraldehyde (GA) in growth medium for 15 min at room temperature, then washed and resuspended in PBS (140 mM NaCl, 27 mM KCl, 10 mM Na₂HPO₄·2H₂O, 2 mM KH₂PO₄ pH 7.2). Cell concentration was adjusted to an OD600 of 0.6 and samples were incubated in 75 μl PBS containing 30 mg/ml BSA to block non-specific sites on the cell surface for 30 min at 37°C. Then antibodies were added, either anti-FLAG (M2, Sigma) or anti-myc (9E10, Roche) at an end concentration of 20 μg/ml, and samples were incubated at 37°C for 30 min. The cells were washed 3 times with 2 volumes of PBS containing 30 mg/ml BSA, and then incubated in 1 volume with
Donkey-anti-Mouse-Cy3 conjugate (Jackson ImmunoResearch) at 10 μg/ml end concentration for 30 min at 37°C, washed 3 times with 2 volumes PBS and imaged.

**Fluorescent labeling of living cells**

Cells were put on ice, and an amount of cells equivalent to 1 ml OD600 of 0.3 (around 2·10^8 cells) was taken for labeling. Cells were collected in all cases by centrifugation at 20,000 x g for 5 min at 4°C. The pellet was resuspended in 75 μl PBS at room temperature (RT) with 0.1% BSA. The cells are left at RT for 10 min to block aspecific sites on the cell surface. Then either biotinylated anti-FLAG (Sigma) was added (50 μg/ml) (FLAG constructs), or streptavidin-Alexa 488 (Molecular Probes) was added directly (40 μg/ml) (SA-1 constructs). Cells were incubated at RT for 30 min. The cells were spun down and washed twice with 0.5 ml PBS, and resuspended in 150 μl PBS. For the cells labeled with biotinylated FLAG, streptavidin-Alexa 546 (Molecular Probes) was added (5 μg/ml), and samples were incubated for 30 min at RT. Then, PBS (0.85 ml) was added and the cells were pelleted. After a second wash with 0.5 ml PBS, the cells were fixed in 1 ml PBS with 2.8% formaldehyde and 0.042% glutaraldehyde, washed in 1 volume of PBS and resuspended in 0.1 volume PBS. The cells were either imaged directly or stored at 4°C over night before imaging.

**Fluorescence Microscopy**

Cells were immobilized on 1% agarose in water slabs-coated object glasses as described by (Koppelman et al. 2004) and photographed with a CoolSnap fx (Photometrics) CCD camera mounted on an Olympus BX-60 fluorescence microscope through a UPLANFl 100x/1.3 oil objective (Japan). Images were taken using the public domain program Object-Image2.19 by Norbert Vischer (University of Amsterdam, http://simon.bio.uva.nl/object-image.html), which is based on NIH Image by Wayne Rasband. In all experiments the cells were first photographed in the phase contrast mode. Then a fluorescence image was taken using either a green excitation/red emission (U-MNG, ex. 530–550 nm), or a blue excitation/green emission filter cube (U-MNB or EGFP, ex. 470–490 nm).
### Differential surface display of peptides

<table>
<thead>
<tr>
<th>Strains</th>
<th>Genotype</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>LMC500 (MC4100 lysA)</td>
<td>F, araD139, Δ(argF-lac)U169, deoC1, flbB5301, ptsF25, rbsR, relA1, rpsL150, lysA1</td>
<td>(Taschner et al. 1988)</td>
</tr>
<tr>
<td>MC1061</td>
<td>F, araD139, Δ(ara-leu)7696, ΔlacX74, galU, galK, hsdR2 (rL, mR), mcrA0, mcrB1, rpsL, spoT1</td>
<td>(Casadaban and Cohen 1980)</td>
</tr>
<tr>
<td>MC1061 ΔOmpA</td>
<td>MC1061 ΔOmpA</td>
<td>(Bessette et al. 2004)</td>
</tr>
<tr>
<td>DH5α</td>
<td>F, endA1, hsdR17( rL, mR), supE44, thi-1, recA1, gyrA, relA1, Δ(lacZYA-argF)U169, deoR, Φ80 lacZΔM15</td>
<td>Lab collection</td>
</tr>
<tr>
<td>DH5α-Z1</td>
<td>DH5α LacIq', TetR'</td>
<td>(Lutz and Bujard 1997)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Plasmids</th>
<th>Proteins expressed</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>pMD005</td>
<td>pTHV037 OmpA-177</td>
<td>This work</td>
</tr>
<tr>
<td>pGV1</td>
<td>pTHV037 OmpA-177 2xmyc in Loop 2</td>
<td>This work</td>
</tr>
<tr>
<td>pGV2</td>
<td>pTHV037 OmpA-177 3xFLAG in Loop 2</td>
<td>This work</td>
</tr>
<tr>
<td>pGV3</td>
<td>pTHV037 OmpA-177 2xmyc in Loop 3</td>
<td>This work</td>
</tr>
<tr>
<td>pGV4</td>
<td>pTHV037 OmpA-177 3xFLAG in Loop 3</td>
<td>This work</td>
</tr>
<tr>
<td>pGI9</td>
<td>pTHV037 OmpA-LEDPPAEF</td>
<td>This work</td>
</tr>
<tr>
<td>pGI6</td>
<td>pTHV037 OmpA-LEDPPAEF containing 3xFLAG in Loop 3</td>
<td>This work</td>
</tr>
<tr>
<td>pB33OmpA14-SA1</td>
<td>pBAD33 OmpA SA-1 in Loop 1</td>
<td>(Bessette et al. 2004)</td>
</tr>
<tr>
<td>pGV28</td>
<td>pTHV037 OmpA-177-SS SA-1 in Loop 1</td>
<td>This work</td>
</tr>
<tr>
<td>pGV32</td>
<td>pTHV037 OmpA-LEDPPAEF 3xFLAG in Loop 2</td>
<td>This work</td>
</tr>
<tr>
<td>pGV33</td>
<td>pTHV037 OmpA-LEDPPAEF SA-1 in Loop 1</td>
<td>This work</td>
</tr>
<tr>
<td></td>
<td>pTHV037 OmpA-177</td>
<td>(Den Blaauwen et al. 2003)</td>
</tr>
<tr>
<td></td>
<td>pTHV037 OmpA with a weakened IPTG inducible promoter</td>
<td></td>
</tr>
</tbody>
</table>

**Table 1.** All strains and plasmids used for this study.
Chapter 3

Results

Design of loop insertions

A topology model of the transmembrane domain of OmpA is shown in Figure 3.1. For locations in loop 2 and loop 4 (after Y63, G70 and I153 respectively), it has been shown that small (up to 21 residue) peptides can be inserted without any reduction in protein levels (Cole et al. 1983; Freudl 1989) and membrane incorporation (after G70 and I153, (Freudl 1989)). For loop 2, reported inserted peptides are listed in Table II. Initially, we used only the OmpA TM domain, but later also the periplasmic domain was added. 3xFLAG and 2xmyc peptides were chosen as epitope tags (Table II). We will refer to them as FLAG and myc from now on. High-affinity monoclonal antibodies are commercially available for these epitopes. SWISS-Model (Guex and Peitsch 1997) was used to predict OmpA folding after peptide insertion. First, a continuous model was generated of the first 176 residues, based on the published crystal structures of OmpA-171 (Figure 3.51A). Then, models were generated of loop insertions after different residues in the protein, and the resulting (static) loop conformations were examined for their propensity to extend away from the

<table>
<thead>
<tr>
<th>Name</th>
<th>Target</th>
<th>Loop</th>
<th>AA</th>
<th>Sequence</th>
<th>-/+ Charge</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 AA</td>
<td>pronase</td>
<td>L2</td>
<td>8</td>
<td>NWLGRMPY</td>
<td>0/1</td>
<td>(Cole et al. 1983)</td>
</tr>
<tr>
<td>21 AA</td>
<td>proteinase K</td>
<td>L2</td>
<td>21</td>
<td>AGMQAYRIRA RYPGLFSRPA</td>
<td>0/4</td>
<td>(Freudl 1989)</td>
</tr>
<tr>
<td>3xFLAG</td>
<td>mAb M2</td>
<td>L2/3</td>
<td>22</td>
<td>DYKHDHG-DYKHDHI-DYKDDDK</td>
<td>-11/4</td>
<td>This study</td>
</tr>
<tr>
<td>2xmyc</td>
<td>mAb 9E10</td>
<td>L2/3</td>
<td>20</td>
<td>EQKLISEEDL EQKLISEEDL</td>
<td>-8/2</td>
<td>This study</td>
</tr>
<tr>
<td>SA-1</td>
<td>Streptavidin</td>
<td>L1</td>
<td>15</td>
<td>RLEICQNVYLYGLT</td>
<td>-1/1</td>
<td>(Bessette et al. 2004)</td>
</tr>
</tbody>
</table>

Table II. OmpA peptide insertions in loop 2 as reported in literature, and the insertions that are described in this study.
Differential surface display of peptides

Figure 3.1. Topology model of the TM domain of OmpA (OmpA-177) (adapted from (Pautsch and Schulz 1998)). Black arrowheads indicate positions where peptides have been inserted: after N26 (Bessette et al. 2004) and this study, Y63 (Cole et al. 1983), G70 (Freudl 1989) and this study, N109 this study, and I153 (Freudl et al. 1986; Freudl 1989). Residues present in beta-strands are indicated with squares. Other residues are presented as circles.

membrane normal axis. Models were generated of insertions in loop 2, 3 and 4. Finally, loop 3 was chosen, since the computer-generated model of an inserted FLAG peptide after N109 predicted the largest distance away from the surface (Figure 3.1C).

To be able to compare the performance of our constructs with results reported in literature, we also constructed loop 2 insertions with the FLAG and myc epitopes. For loop 2, insertions after G65, G70, Y72 and Q75 were modeled. In the end G70 was chosen, because (a) as mentioned, it was shown that at this location, a 21-residue peptide could be inserted without any negative effects on membrane insertion (Freudl 1989), and (b) modeling with SWISS-Model of these four locations predicted that at G70, the loop would be extended away from the surface more than at the other three positions in loop 2 (Figure 3.1B).

During the course of this work, a loop 1 peptide insertion in full-length OmpA was described in the literature (Bessette et al. 2004). The position of the insertion is indicated
Chapter 3

in Figure 3.1 (after N26). As mentioned in the introduction, the SA-1 peptide tag (listed in Table I) binds streptavidin directly with high affinity. Since this peptide was neutrally charged and could be conveniently labeled with fluorescent streptavidin, we decided to compare this loop insertion variant with our constructs. Therefore, it was cloned into our expression vector, both as a truncated TM domain and as a full-length protein, and assayed in the same way as the FLAG/myc insertions.

**Growth of cells expressing OmpA-177 loop insertion proteins**

The constructs were tested for expression in LMC500 (MC4100 ΔlysA), a well characterized wild type strain (Taschner et al. 1988; Peters et al. 2003), MC1061 ΔOmpA (Bessette et al. 2004), an OmpA knockout strain, and in its parental strain MC1061 (Casadaban and Cohen 1980). To test to what extent the proteins could be expressed without affecting the growth rate, the growth was followed by measuring the optical density before and after addition of
the inducer IPTG. Growth curves from a typical experiment are shown in Figure 3.2A. In this experiment, cells carrying an empty vector were compared with cells expressing an OmpA-177 protein with a FLAG insertion in loop 2. Without IPTG induction, all growth curves appear identical. Approximately 15 minutes after addition of IPTG however, the OmpA-177 protein with a FLAG insertion in loop 2 shows a lag phase where growth stops for approximately 30 min, after which growth continues normally. Addition of IPTG did not affect the growth rate of the control cells carrying an empty vector. In Figure 3.2B, growth curves from a second experiment are shown where induction of two TM domain variants, a FLAG insertion either in loop 2 or loop 3, are compared. For the loop 3 insertion, after induction with IPTG no lag phase is observed and the growth curve is similar to the growth curve of uninduced cells (Figure 3.2A).

The induction experiment was performed for all the OmpA TM domain variants and the results are listed in Table III. It can be concluded that in strain LMC500, induction of the loop 2 (FLAG/myc), and to a lesser extent, the loop 1 (SA-1), but not the loop 3 (FLAG/myc) insertions caused a lag phase of 30-60 min after which growth continued normally. Surprisingly, this lag phase was absent both in MC1061 and in MC1061ΔOmpA. Induction with 0.3 mM IPTG of the loop 2 (FLAG), or loop 1 (SA-1) in these strains had no effect on the growth rate at all. Because in LMC500 and MC1061, similar expression levels were detected on immunoblots, it appears that strain MC1061 and its derivative

<table>
<thead>
<tr>
<th>Construct</th>
<th>Peptide</th>
<th>Location</th>
<th>Growth after induction</th>
<th>Mass on PAGE/blot (kDa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD005</td>
<td>none</td>
<td>NA</td>
<td>++</td>
<td>19</td>
</tr>
<tr>
<td>GV2</td>
<td>3xFLAG</td>
<td>loop 2</td>
<td>--</td>
<td>25</td>
</tr>
<tr>
<td>GV4</td>
<td>3xFLAG</td>
<td>loop 3</td>
<td>+</td>
<td>25 and 27</td>
</tr>
<tr>
<td>GV1</td>
<td>2xmyc</td>
<td>loop 2</td>
<td>--</td>
<td>25</td>
</tr>
<tr>
<td>GV3</td>
<td>2xmyc</td>
<td>loop 3</td>
<td>+</td>
<td>25 and 27</td>
</tr>
<tr>
<td>GV28</td>
<td>SA-1</td>
<td>loop 1</td>
<td>-</td>
<td>21</td>
</tr>
</tbody>
</table>

Table III Growth and molecular mass as detected on immunoblot after induction with 0.3 mM IPTG of LMC500 expressing OmpA proteins with loop insertions. "Growth after induction" indicates the presence and extent of a lag phase after adding inducer (++ no lag phase, -- strong lag phase).
MC1061ΔOmpA are more able to cope with the perturbation caused by the induction (see also discussion).

**Expression of OmpA-177 loop insertion proteins**

Samples, harvested at the end of the induction experiment described above were analyzed by SDS-PAGE and immunoblotting. For the FLAG and myc constructs, a blot is shown in Figure 3.S2. Based on the immunoblots it was clear that all four variants were expressed, no degradation bands were observed, and all ran at a similar height that was retarded with respect to their calculated molecular weight (approx. 3-4 kDa). This was also observed for full-length constructs that carried a FLAG insertion (see below). The reduced mobility on gel was attributed to the high amount of negative charge in the FLAG and myc peptides. Unexpectedly, unprocessed (precursor) proOmpA-177 was also detected in uninduced samples as well as in induced samples expressing either FLAG or myc in loop 3 (see also Figure 3.S3). The difference in expression levels between induced and uninduced samples was a factor 2-5 fold (all protein levels were determined from immunoblot by densitometry.)
Differential surface display of peptides

using ImageJ, data not shown). Without induction, for FLAG as well as myc, about 25% of
the loop 3 constructs detected were not processed.

Induced OmpA-177 without loop insertion was directly visible on a Coomassie
Brilliant Blue (Coomassie) stained SDS-PAGE (see Figure 3) and could be detected on
immunoblot using a polyclonal antibody against OmpA, but the band was very weak
compared to endogenous (full-length) OmpA (data not shown). From this, we conclude
that this polyclonal antibody primarily recognizes the periplasmic domain of OmpA. Also,
an attempt was made to detect the streptavidin binding peptide SA-1 construct on blot
using a Streptavidin-HRP conjugate, but only the endogenous cytoplasmic biotinylated
biotin carrier protein BCCP was detected (data not shown). Apparently, streptavidin does
not bind sufficiently strong to the denatured conformation of SA-1.

To be able to directly compare the amounts of protein in the membrane, membrane
fractions were isolated of cells expressing the various OmpA TM domain variants (Figure
3.3). Induction of both OmpA-177 and OmpA-177 SA-1 constructs resulted in strong bands
at roughly their expected height (calculated MW of OmpA-177 is 19.3 kDa and of OmpA-
177 SA-1 is 21.1 kDa). Surprisingly, no bands could be identified that corresponded to the
FLAG or myc constructs.

To determine how much of the expressed construct is present in the envelope
fractions put on gel, we compared soluble (S) to membrane (M) fractions. Although not
visible on a Coomassie stained gel, immunoblots of the fractions showed that the FLAG
and myc constructs were present, and fractionated predominantly to the membrane
fraction (Figure 3.S3). We conclude that these constructs are present in the cell at greatly
reduced amounts (less than 10% as judged from the Coomassie stained gel) compared to
wild type OmpA-177 or the OmpA-177-SA1. This could either be due to a reduced
synthesis rate (not expected for FLAG and myc tags), due an increased degradation rate
(see also below) or both.

Role of the periplasmic domain

To our knowledge, all OmpA loop insertions reported in the literature have been made in
full-length OmpA. To establish whether the periplasmic domain might play a role in
preventing a reduction in protein levels after FLAG or myc insertion in the transmembrane
domain, full-length constructs were made for the FLAG epitope in loop 2 and 3, and the
SA-1 insertion in loop 1. These constructs were transformed to LMC500 and MC1061
ΔOmpA and were subjected to the same induction experiment as for the OmpA TM domain variants. Without induction, all full-length constructs grew normally in both genetic backgrounds. After induction, the growth rate remained unaffected for all full-length OmpA loop insertion constructs in the MC1061 ΔOmpA background whereas expression in LMC500 resulted in growth curves similar to those obtained for the OmpA-177 constructs (only tested for the loop 3 FLAG insertion).

The full-length constructs were detected both on Coomassie stained gel (Figure 3.4A) as well as on immunoblot using a polyclonal antibody that recognizes the periplasmic domain of OmpA (Figure 3.4B, Figure 3.54). As with the FLAG OmpA-177 proteins, full-length OmpA FLAG constructs had a higher apparent molecular weight than calculated. Comparing soluble to membrane fractions using immunoblots yielded similar results as for the OmpA-177 variants, with the majority of each construct fractionating to the membrane fraction, except loop 3, which was divided over the soluble and membrane
Differential surface display of peptides

Figure 3.5. FLAG insertions, either in Loop 2 or 3, are present at approx. 5-10% relative to either the full-length OmpA without insertion or the full-length OmpA with a SA-1 insertion in Loop 1. The levels were quantified from immunoblots by densitometry using ImageJ and are normalized relative to the stronger band. Both total cell lysates and membrane fraction were quantified. For 3xFLAG in Loop 3, compared with full-length OmpA without insertion, no IPTG was added. For 3xFLAG in Loop 2, compared with SA-1 in Loop 1, constructs were induced with 0.3 mM IPTG.

Again, the FLAG constructs appear greatly reduced compared to both the OmpA without insertion and the OmpA with an SA-1 insertion, all expressed from plasmid. The intensities of the anti-OmpA bands from Figure S4 were quantified using ImageJ and plotted as bar graphs in Figure 3.5. Together with Figure 3.4A, it can be concluded that full-length OmpA constructs with FLAG insertions either in loop 2 or loop 3, are present at approximately 5-10% compared to full-length OmpA without insertion or the full-length OmpA carrying a SA-1 insertion, respectively.

Apart from intact construct, the immunoblots probed with anti-OmpA antibody revealed a strong band around 17 kDa (the expected size of the periplasmic domain) that fractionates to the soluble fraction (Figure 3.4B). This band was absent from samples containing induced full-length OmpA without insertion and weakly detected in induced full-length OmpA with the SA-1 insertion (data not shown). From this we conclude that the degradation band is specific and that it is related to the reduced protein levels of the FLAG constructs. In addition, the FLAG constructs were detected using anti-FLAG antibody (Figure S4 and not shown). The 17 kDa degradation band did not react with anti-FLAG (the
smallest degradation band detected with anti-FLAG ran around 27 kDa). Apparently, the periplasmic domain of OmpA was cleaved from the TM domain and the latter was to a large extent degraded.

Taken together, it can be concluded that both the full-length and the OmpA-177 constructs with a FLAG insertion are present in greatly reduced amounts, compared to without insertion or with a SA-1 insertion. Therefore, addition of the periplasmic domain does not improve protein levels of the FLAG insertion. Furthermore, the reduction in protein levels is, at least partly, caused by degradation, as observed on immunoblots.

**OM incorporation of truncate and full-length constructs**

To study whether the OmpA variants, present in the membrane fraction, have obtained their native form, we examined their heat-modifiability. The native form of the OmpA TM domain is a compact β-barrel that has a particularly tight fold with a half life of 30 min when heated to 72°C in 2% SDS (Koebnik 1999). When heated in SDS at lower temperatures (e.g. 50°C) the β-barrel becomes soluble without unfolding and migrates faster through the gel (30 kDa) relative to its denatured form, which runs at the expected molecular weight (35 kDa). This effect is called heat modifiability (Reithmeier and Bragg 1974) and it is a general property of β-barrels. Various techniques have been used to
confirm that the 30 kDa form corresponds to the native fold of OmpA (for references consult Arjara 2007). It is generally assumed that in vivo, the native form of OmpA is generated only after proper insertion into the outer membrane (Ried, 1994).

Cell membranes containing IPTG-induced OmpA-177 or OmpA-177 SA-1 proteins, expressed in LMC500 or MC1061 ΔOmpA were either heated in sample buffer for 5 min at 99°C or for 15 min at 50°C, before being separated on a 15% SDS-PAGE and immunoblotted. Indicated are: (p) processed, unfolded, (m) matured, properly folded and (u) unprocessed, unfolded. In (A) 0.1 µg/ml anti-FLAG was used for the induced Loop 2 construct, and 1 µg/ml anti-myc and 0.5 µg/ml anti-FLAG were used for the uninduced Loop 3 constructs. In (B), 1:10000 anti-OmpA, and 0.1 µg/ml anti-FLAG was used.

**Figure 3.7.** OmpA-177 domain variants with FLAG or myc epitopes and a full-length OmpA variant with a FLAG epitope are predominantly heat-modifiable. Cell envelopes of various OmpA-177 TM domain variants (A) and the full-length Loop 2 FLAG construct (B) were either heated in sample buffer for 5 min at 99°C or for 15 min at 50°C, then applied on gel, separated by SDS-PAGE and stained with Coomassie (Figure 3.6). Note that both OmpC and OmpF do not become soluble at 50°C and are therefore only visible in samples heated at 99°C (Ried et al. 1994). As expected, the endogenous OmpA of LMC500 is fully heat-modifiable. Furthermore, the OmpA-177 protein, but not the OmpA-177 containing the SA-1 insertion, shows the aberrant heat-modifiability already observed in the literature for OmpA-171 (Ried et al. 1994), where the folded protein migrates slower than the unfolded protein (see also discussion). Finally, the OmpA-177 SA-1 protein is also fully heat-modifiable. We conclude that the majority, if not all, of both constructs have reached their native form.
For the FLAG and myc constructs, because of their low levels in the cell, immunoblotting was used to visualize their heat-modifiability (Figure 3.7). The OmpA TM domain constructs with FLAG or myc are all predominantly heat-modifiable (Figure 3.7A, indicated “mature”). As expected, the loop 3 precursor bands (indicated "unprocessed"), present in the membrane fraction, are not at all heat-modifiable. Also a full-length OmpA construct carrying a loop 2 FLAG insertion was found to be fully heat-modifiable (Figure 3.7B). We conclude that all FLAG and myc constructs are at least partially heat-modifiable, and thus can be properly incorporated in the outer membrane.

**Surface display of loop insertions: fluorescent labeling of cells**

To determine the accessibility on the cell surface of the inserted antigenic peptides, both fixed and living cells were labeled. Cells carrying the FLAG and myc in either loop 2 or 3 of OmpA-177 were induced with 0.3 mM IPTG, fixed and stained with monoclonal anti-FLAG or monoclonal anti-myc. As a negative control, the primary antibody was left out, and no fluorescence was observed for any of these samples. All four constructs were detected on the bacterial cell surface (Figure 3.8S). Loop 2 insertions show more staining at the poles, whereas loop 3 insertions are more homogeneous.

Living cells were labeled using a biotinylated variant of the anti-FLAG antibody. Labeling of living cells was performed because it was found that fluorescent streptavidin (needed for the SA-1 peptide) penetrated fixed cells to show a nucleoid-like staining (data not shown). The cells could be fixed after labeling to preserve the staining.

Results of labeled, uninduced cells carrying either OmpA-177 FLAG (loop 3) or the full-length OmpA-FLAG (loop 3) showed that both have comparable levels of antibody-accessible FLAG epitope on their surface (Figure 3.8A, B). This provides further evidence that adding the periplasmic domain does not result in increased stability of the protein. The limited increase in fluorescence after induction correlates with a modest increase of intact protein, and a larger increase of the 17 kDa degradation band as detected on immunoblot (data not shown).
Finally, living LMC500 cells expressing OmpA-177-SA1 were directly labeled with fluorescent streptavidin, fixed and imaged (Figure 3.8C). To be able to compare with and without induction directly, a short exposure time (150 ms) was chosen. Without induction staining was homogeneous along the perimeter of the cells. After induction (and after recovery from the lag phase that occurs in LMC500, see earlier), fluorescence increased markedly, and during labeling, strong streptavidin-mediated cross-linking between cells
occurred, leading to clumps. Overall, we conclude that all the constructs are detected on the cell surface, but for FLAG, and likely also myc, the increase after induction is reduced due to degradation, whereas for SA-1, both efficient labeling and a strong effect of induction on the surface display is observed.
Discussion

Reduced protein levels of FLAG or myc loop insertions in OmpA

In this work we have characterized peptide insertions in the OmpA protein, both in TM domain constructs (OmpA-177) and full-length constructs. As insertions we used the popular FLAG and myc epitopes, and a streptavidin binding peptide SA-1. It has been demonstrated that small (up to 21-residue) peptides could be inserted in loop 2 of OmpA without reduction in protein levels or membrane incorporation (Cole et al. 1983; Freudl 1989). Unexpectedly, introducing a FLAG or myc peptide at this location in the OmpA protein reduced the protein levels with approximately 90% (Figure 3.3, Figure 3.5). However, the majority of the intact protein was inserted properly in the OM, as judged by its heat-modifiability (Figure 3.7A). In contrast, insertion of the SA-1 peptide in loop 1 did not reduce protein levels, similar to the reported insertions in loop 2 (Table II).

It could be argued that the observed differences are due to over-expression of the proteins. However, our expression vector (a weakened pTrc99A (Den Blaauwen et al. 2003)) produces less than $5 \times 10^3$ proteins in the absence of IPTG (Aarsman et al. 2005), and already at these low expression levels the marked difference in protein level between OmpA with a FLAG insertion and OmpA without insertion is observed (Figure 3.5). This suggests that introducing the FLAG epitope leads to an intrinsically reduced protein level, independent of the induction level.

What could be the reason of the observed reduction in protein levels of the FLAG and myc constructs? Since both the FLAG and myc epitopes are effectively negatively charged (Table II), they might interact unfavorably with the negatively charged LPS in the OM, or with the Omp85 protein complex responsible for OM insertion (Bos et al. 2007). We speculate that a reduced rate of OM incorporation might cause a buildup of unincorporated (misfolded) OmpA proteins, whose subsequent degradation would explain the reduced cellular levels of the FLAG and myc constructs reported here.

Unexpectedly, in exponentially growing cells without IPTG, about 25% of the loop 3 insertions are not processed. Since OmpA is mostly post-translationally translocated to the periplasm via the Sec system (Eisner et al. 2003), for the loop 3 construct perhaps some
tertiary structure forms in the cytoplasm that delays, or interferes with, its translocation (Mitra et al. 2006). However, induction of constructs with FLAG in loop 2 or loop 3 results in similar amounts of processed OmpA (Figure 3.S2), and in similar amounts of FLAG epitope detected on the bacterial surface (Figure 3.S5). This suggests that after processing and release into the periplasm, both proteins behave in a similar way.

Overexpression of engineered OmpA variants in LMC500 versus MC1061

Surprisingly, induction of either (FLAG or myc) loop 2 constructs or the OmpA-177-SA1 in LMC500 (MC4100 lysA) affects growth rate profoundly. It is difficult to understand that loop 2 FLAG/myc and loop 1 SA-1 constructs cause a similar effect on growth rate in LMC500, since their amounts differ 10-fold. Perhaps the cell regulates the amount of proteins in the OM that are tolerated (little in the case of FLAG/myc, a lot in the case of SA-1). When IPTG induction disturbs this balance, the observed lag period of 30 min might reflect a period in which the cell adapts and restore this balance, after which the cells continue growth.

Accumulation of misfolded OMPs in the cell envelope causes the activation of the \( \sigma^E \) controlled extracytoplasmic stress response (Hasselblatt et al. 2007) that down-regulates OMP expression ((Rhodius et al. 2006)). Indirect evidence for \( \sigma^E \) activation upon IPTG induction of our OmpA loop insertion variants comes from the membrane fractions shown in Figures 3.3 and 3.4, where OMP expression (OmpC/F and OmpA) is consistently down-regulated after IPTG induction, but only for loop insertion variants.

In the different genetic background of strain MC1061 and its derivative MC1061ΔOmpA, expression levels were similar to LMC500, but the growth rate was unaffected upon IPTG induction (data not shown). It has been shown that the \( \sigma^E \) transcription factor is also controlled by intracellular ppGpp levels (Costanzo and Ades 2006). MC1061 has the spoT1 mutation, that abolishes the ppGppase activity of SpoT and results in increased levels of (p)ppGpp (Cashel, 1996). This could offer an explanation for the observed robustness of MC1061 towards overexpression of the OmpA loop insertion constructs. If MC1061 is better able to cope with folding stress in the periplasm (e.g. by having its stress response genes already expressed, or in higher levels), the balance can be restored immediately, without disturbing the growth rate. Whatever the molecular mechanism may be, our results indicate that MC1061 is a strain of choice when overexpressing engineered
Differential surface display of peptides

outer membrane proteins such as OmpA.

“Aberrant” heat-modifiability versus normal heat-modifiability

Finally, our results provide insight on the aberrant heat-modifiability observed for 8-stranded β-barrels such as OmpA-171, OmpA-177 and NspA (Vandeputte-Rutten et al. 2003). Heat-modifiability is termed “aberrant” when the unfolded form migrates faster through the gel compared to the folded form. Surprisingly, for the OmpA-177 insertion variants (SA-1, FLAG or myc) heat-modifiability is “normal” again (Figure 3.6). Comparing the mobility of OmpA-177 to OmpA-177-SA-1, we find that the folded barrels run at almost similar height, as if the extra residues of SA-1 were absent, whereas after boiling, OmpA-177-SA-1 is retarded with respect to OmpA-177 with an amount corresponding to their difference in molecular mass. These results suggest that as more and more residues are added to the OmpA-171 TM domain, the relative positions between the folded and unfolded domains first decrease until they are equal, before increasing again to appear as “normal” heat-modifiability. This predicts that for some rare OMPs, it would seem as if they would not have any heat-modifiability at all.

Summary

Taken together, these data show that both the FLAG and the myc epitopes are displayed in severely reduced amounts on the cell surface. Apparently, OmpA displays not all small peptides equally efficient. Consequently, for applications in which OmpA should be a carrier of randomly generated peptides a negative bias towards certain peptides that share characteristics of FLAG and/or myc, most likely being strongly (negatively) charged, might occur during screening of these surface display libraries.

Acknowledgements

I like to thank Arnold Driessen and Nico Nouwen (University of Groningen, the Netherlands) for the anti-OmpA antibody, Jeffrey Rice (University of California) for the MC1061 ΔOmpA strain and the plasmid carrying the SA-1 peptide, Svetlana Alexeeva for designing constructs pGV1-4 and creating the SWISS-model loop folding predictions, and Genison Isijk for help with cloning pGI6 and pGI9.
Figure 3.S1. Predicted protein structures by SWISS-MODEL of the OmpA transmembrane domain before and after epitope insertion. PDB entries 1g90.pdb, 1bxw.pdb and 1qjp.pdb were used to build the model. (A) OmpA-177 model. (B) OmpA-177 model with 2xmyc inserted in loop 2 after G70. (C) OmpA-177 model with 3xFLAG inserted in loop 3 after N109.

Figure 3.S2. Detection of OmpA-177 TM domain variants with inserted 3xFLAG or 2xmyc peptides on immunoblot. Expression of the variants was induced in LMC500 with 0.3 mM IPTG. From left to right: OmpA-177 loop 2 myc, OmpA-177 loop 2 FLAG, OmpA-177 loop 3 myc and OmpA-177 loop 3 FLAG. For loop 3 variants, unprocessed protein is also present. Left panel: anti-FLAG (3 μg/ml), right panel: anti-myc (3 μg/ml). For this blot, a 12% SDS-PAGE gel percentage was used.
Figure 3.3. The OmpA TM domain constructs are predominantly present in the membrane fraction. Total cell lysate (T) was fractionated into soluble (S) and membrane (M) fractions. Shown are immunoblots of constructs OmpA-177 loop 2 FLAG (induced), OmpA-177 loop 3 myc (uninduced), and OmpA-177 loop 3 FLAG (uninduced). Strain is LMC500, except for loop 2 FLAG, where results from strain LMC500 and MC1061ΔOmpA are shown. Only the relevant portions of the blot are shown. Black line indicates 25 kDa marker band. Antibody concentrations used were 1 μg/ml (anti-myc), and 0.1 μg/ml or 0.5 μg/ml (anti-FLAG) for induced or uninduced FLAG, respectively.
Figure 3.5. The full-length OmpA constructs (except loop 3 FLAG) fractionate predominantly to the membrane fraction. Total cell lysate (T) was fractionated into soluble (S) and membrane (M) fractions. Shown are immunoblots of full-length OmpA constructs carrying a FLAG insertion in loop 2 (d) or loop 3 (c), and an SA-1 insertion in loop 1 (e). Strain was MC1061ΔOmpA. As controls, fractions of LMC500 (endogenous OmpA, OmpA+) (a), and OmpA expressed from plasmid in MC1061ΔOmpA (b) are shown. Only the relevant portions of the blot are shown. Black line indicates 37 kDa marker band. For the wild type OmpA and induced constructs, a 1:10000 dilution was used for the polyclonal antibody against OmpA. For the uninduced construct, a 1:1000 dilution was used. Anti-FLAG was used for the induced and uninduced FLAG constructs at 0.1 μg/ml and 1 μg/ml, respectively. Band intensities in the anti-OmpA blots (b) and (c), and (d) and (e) can be compared directly. Their relative intensities, quantified using densitometry with ImageJ, are shown in Figure 3.5.
Differential surface display of peptides

**Figure 3.55.** Myc and FLAG epitopes are detected on the surface of cells expressing OmpA-177 TM domain variants. Cells induced with 0.3 mM IPTG for expression of OmpA-177 containing either FLAG in loop 2, myc in loop 2, FLAG in loop 3 or myc in loop 3, were fixed and immuno-labeled with antibodies against FLAG or myc. The scale bar corresponds to 2 μm. Image exposure time was 470 ms.
Supplementary Materials and Methods

The signal sequence and the first 177 residues of the mature OmpA protein, coding for the transmembrane domain, were cloned in the expression vector pTrc99A (Amann et al. 1988), modified to decrease the basal expression level (i.e. without inducer) to typically a few thousands proteins per cell (pTHV037, (Den Blaauwen et al. 2003)). OmpA-177 was amplified by PCR from the chromosome of LMC500 using primers proOmpANcoIfw and OmpAHindIIIrv, and ligated in the Ncol and HindIII sites of pTHV037 to create pMD5. The Ncol site introduces after the start Met codon an additional alanine codon. The 3xFLAG and 2xmyc epitope loop insertions in loop 2 and 3 (constructs pGV1-4, see table III) were created using overlap PCR. For instance, to create the 3xFLAG insertion in loop 2 of the OmpA TM domain (pGV2), two separate PCRs, containing a region of overlap, were performed on pMD005. The first PCR with primers proOmpANcoIfw and 3xflagOmpAL2RV, and the second PCR with primers 3xflagOmpAL2FW and OmpAHindIIIrv. The two PCR fragments were then mixed, denatured and annealed to form a duplex at the overlap region, and filled in by DNA polymerase (Advantage, Clontech) for 10 cycles. Subsequently, proOmpANcoIfw and OmpAHindIIIrv were added and the fragments were amplified for another 20 cycles, and either cloned into pGEM-T (Promega), sequenced and then transferred to pTHV037, or cloned directly into pTHV037 using NcoI and HindIII sites. The 3xFLAG insertion in loop 3, and the 2xmyc insertions were created in the same way making use of the following primers: 2xmycOmpAL2RV, 2xmycOmpAL2FW, 2xmycOmpAL3RV, 2xmycOmpAL3FW, 3xflagOmpAL3FW, and 3xflagOmpAL3FW.

pGI9 was created as follows. OmpA-177 was amplified from pMD005 using the primers proOmpANcoIFw and OmpAAgeIHindIIIRV, the PCR product digested by NcoI and HindIII, and was ligated into NcoI/HindIII digested pGV4. This resulted in pGI8 that contains a silent mutation introducing the AgeI site in Pro177, for C-terminal addition of the OmpA periplasmic domain DNA fragment. This fragment was obtained by PCR on the LMC500 chromosome, with primers OaperiAgeIFW and OaperiEcoRIHindIIIRV introducing the AgeI upstream of the periplasmic domain and adding the linker sequence LEDPPAEF downstream. The PCR product was digested with AgeI/HindII and ligated into AgeI/HindIII digested pGI8. pGI6 was created along similar lines: OmpA-177 containing
3xFLAG in loop 3 was amplified from pGV4 using the primers proOmpANcoIFW and OmpAAgeIHindIIIIRV, the PCR product was digested by Ncol and HindIII, and ligated into Ncol/HindIII digested pGV4. This resulted in pGI5. Ligating in the AgeI/HindIII periplasmic domain PCR product, used also for pGI9, created pGI6. pGV28 was created by PCR on pB33OA14-SA1 (Bessette et al. 2004) using primers proOmpANcoIFW and OmpAXhoIPstIRV, digestion by Ncol/XhoI, and ligated into Ncol/XhoI digested pGV14 (unpublished), to get OmpA-177-SS containing SA-1 in loop 1. pGV32 was created by ligation of SphiI digested, gel-purified fragments of pGV2 and pGI9, introducing the 3xFLAG loop 2 insertion into the full-length OmpA. pGV33 was created by ligation of SphiI digested, gel-purified fragments of pGV28 and pGI9, introducing the SA-1 loop 1 insertion into the full-length OmpA. A list of primer sequences is available upon request.